Senior Director, Safety Scientist

About Parabilis Medicines

Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company's lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:

TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact.

For more information,  or follow us on Linked In.

About Parabilis Medicines

Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company's lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:

TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact.

For more information,  or follow us on Linked In.

Parabilis Medicines is seeking an experienced and strategic Senior Director, Safety Scientist to provide scientific leadership for safety surveillance and risk management across our clinical development portfolio. This individual will play a critical role in the ongoing assessment of the benefit-risk profile of investigational products by leading signal detection, safety analyses, and risk management activities while partnering closely with Clinical Development, Regulatory Affairs, Biometrics, and Clinical Operations.

Reporting to the VP, Head of Clinical Safety & Pharmacovigilance, the ideal candidate combines deep pharmacovigilance expertise with strong scientific judgment, excellent communication skills, and the ability to influence cross-functional decision-making in a fast-paced biotech environment.

• Lead safety science activities for assigned development programs, providing strategic input into benefit-risk assessment throughout clinical development.
• Author and maintain Safety Surveillance Plans (SSPs) for Parabilis development assets.
• Perform signal detection and signal management activities, including maintenance of the signal tracker.
• Contribute to literature surveillance to identify, evaluate, and communicate potential safety signals.
• Perform MedDRA SMQ and Preferred Term searches for adverse events of clinical interest to support ongoing safety monitoring.
• Partner with internal stakeholders to leverage visualization tools (e.g., Spotfire) to support safety signal detection and analysis.
• Author…